ClinicalTrials.gg
Not yet recruitingNCT07741864MPIMSUpdated Aug 3, 2026

Effectiveness of a Mindfulness-Based Intervention for Pain Management in Patients With Multiple Sclerosis (MPIMS).

An interventional study of Mindfulness-based intervention and Educational intervention in Multiple Sclerosis, Pain and Pain Management, sponsored by Hospital Universitario Virgen Macarena. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Hospital Universitario Virgen Macarena · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.

Planned enrollment
119th of 202
84 · median 137
Started
2026
with 11 others
No phase
68 of 230
22 open now
Primary completion
2027-04
later than 32 of 55 live
Registered
223rd of 230
by date

Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 119th largest by planned enrollment of the 202 interventional ones that give a count, is one of 12 that started in 2026, is one of 68 with no phase, reaches primary completion later than 32 of the 55 other live ones, and was the 223rd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Multiple Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether a mindfulness-based intervention is effective for reducing pain in adults with multiple sclerosis. It will also assess whether this intervention improves other symptoms commonly associated with pain, such as fatigue, sleep disturbances, anxiety, depression, and quality of life.

The main questions it aims to answer are:

  • Does a mindfulness-based intervention reduce pain intensity in people with multiple sclerosis?
  • Does the intervention improve fatigue, sleep quality, emotional well-being, quality of life?
  • Does the effectiveness of the intervention differ according to the type of pain experienced by participants? Researchers will compare a mindfulness-based intervention with an educational program to determine whether mindfulness provides additional benefits for pain management in people with multiple sclerosis.

Participants will:

  • Be randomly assigned to either the mindfulness intervention group or the educational control group.
  • Complete assessments before the intervention, immediately after the intervention, and at 1-month and 3-month follow-up visits.
  • If assigned to the mindfulness group, attend eight weekly 2.5-hour group sessions plus one 6-hour retreat, either in person or online.
  • If assigned to the control group, attend two 2-hour educational sessions during the study period.
  • Complete questionnaires evaluating pain, fatigue, physical function, anxiety, depression, sleep quality, quality of life, and mindfulness throughout the study.
03

Conditions studied

  • Multiple Sclerosis
  • Pain
  • Pain Management

Keywords

  • Multiple Sclerosis
  • Pain
  • Mindfulness
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 80 years.
  • Diagnosis of multiple sclerosis with an Expanded Disability Status Scale (EDSS) score between 1.0 and 7.0.
  • Presence of pain.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment.
  • Diagnosed psychiatric disorders (e.g., schizophrenia or personality disorders).
  • Participation in another non-pharmacological intervention specifically aimed at pain management.
  • If receiving stable pain medication, treatment must have been maintained for at least 4 months before enrollment.
  • Unwillingness to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Mindfulness Group

    Participants will receive a Mindfulness intervention specifically designed for pain management in people with multiple sclerosis.

    Other: Mindfulness-based intervention

  • Active comparator
    Educational Group

    Participants will receive an active educational intervention for pain management consisting of two group sessions

    Other: Educational intervention

Interventions

  • OtherMindfulness-based intervention

    Group-based mindfulness intervention specifically designed for pain management in people with multiple sclerosis. The program includes pain neuroscience education, cognitive pain management strategies, guided meditation, active visualization techniques, mindfulness-based stretching exercises, and mindful yoga.The intervention consists of eight weekly group sessions lasting 2.5 hours each, followed by a 6-hour mindfulness retreat. Participants may attend the sessions either in person or online.

  • OtherEducational intervention

    Educational intervention consists of two 2-hour group sessions on multiple sclerosis and pain management, delivered once every 4 weeks during the 8-week intervention period.

06

What researchers measure

Primary outcomes

  1. Intensity of pain

    The intensity of pain will be assessed using the Visual Analogue Scale (VAS). The VAS is a self-reported measure of pain intensity in which participants rate their current pain on an 11-point scale ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicate greater pain intensity.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  2. Dimensions of pain

    The dimensions of pain will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ). The SF-MPQ is a 15-item instrument that assesses the qualitative characteristics of pain through 11 sensory and 4 affective descriptors, each rated on a 4-point scale from 0 (none) to 3 (severe). Total score ranges from 0 to 45, with higher scores indicating greater pain intensity and more severe pain qualities.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  3. Impact of pain on daily functioning

    The impact of pain on daily functioning will be assessed using the Pain Self-Efficacy Questionnaire (PSEQ). The PSEQ is a 10-item questionnaire designed to evaluate an individual's confidence in performing daily activities despite pain. Each item is rated on a 7-point Likert scale ranging from 0 (not at all confident) to 6 (completely confident), yielding a total score from 0 to 60, with higher scores indicating greater pain self-efficacy.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  4. Presence of neuropathic pain

    The presence of neuropathic pain will be assessed using the Douleur Neuropathique 4 (DN4) questionnaire. The DN4 is a 10-item questionnaire consisting of 7 interview items assessing symptoms characteristic of neuropathic pain and 3 clinical examination items evaluating hypoesthesia to touch, hypoesthesia to pinprick, and pain evoked by brushing. Each item is scored as 0 (absent) or 1 (present), yielding a total score ranging from 0 to 10. A total score of ≥4 is indicative of neuropathic pain.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  5. Emotional and cognitive impact of pain

    The emotional and cognitive impact of pain will be assessed using the Pain Catastrophizing Scale (PCS). The PCS is a 13-item self-administered questionnaire that assesses pain catastrophizing by evaluating negative thoughts and emotional responses associated with pain. It comprises three subscales: rumination (4 items), magnification (3 items), and helplessness (6 items). Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (all the time), yielding a total score ranging from 0 to 52, with higher scores indicating greater levels of pain catastrophizing.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  6. Severity of pain

    The severity of pain will be assessed using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self-report questionnaire that assesses pain severity, pain interference with daily activities, and pain characteristics. It consists of 9 items. Pain severity is assessed using four items rated on an 11-point numeric rating scale (0 = "no pain" to 10 = "pain as bad as you can imagine"), while pain interference is assessed using seven items rated from 0 ("does not interfere") to 10 ("completely interferes"). Higher scores indicate greater pain severity.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

Secondary outcomes

  1. Physical function

    Physical function will be assessed using the PROMIS-29 Profile, a patient-reported outcome measure that evaluates physical, mental, and social health, including physical function and pain interference. The PROMIS-29 consists of 29 items distributed across eight domains. The first seven domains are scored using a 5-point Likert scale, with four items per domain. The eighth domain assesses pain intensity using a single item scored on an 11-point numeric rating scale (0-10). Raw scores for each domain can be converted into standardized T-scores (mean = 50, SD = 10), with higher scores indicating more of the construct being measured.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  2. Fatigue

    Fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS), a patient-reported outcome measure that evaluates the impact of fatigue on physical, cognitive, and psychosocial functioning.The scale consists of 21 items, each rated on a 5-point Likert scale ranging from 0 (never) to 4 (almost always). The total score ranges from 0 to 84, with higher scores indicating greater fatigue.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  3. Depressive symptoms

    Depressive symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9), a self-administered questionnaire that assesses the presence and severity of depressive symptoms over the previous two weeks. The questionnaire consists of 9 items rated on a 4-point Likert scale, ranging from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  4. Anxiety

    Anxiety will be assessed using the Generalized Anxiety Disorder-7 (GAD-7), which assesses the severity of anxiety symptoms. It consists of seven items rated on a 4-point Likert scale (0 = "not at all" to 3 = "nearly every day"). Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. Scores of 0-4 indicate minimal anxiety, 5-9 mild anxiety, 10-14 moderate anxiety, and 15-21 severe anxiety.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  5. Sleep disturbance

    Sleep disturbance will be assessed using the PROMIS Sleep Disturbance Short Form 6a (PROMIS-SD SF 6a). The PROMIS-SD SF 6a assesses the individual's subjective perception of sleep quality, sleep depth, and sleep restoration over the previous 7 days. It consists of six items rated on a 5-point Likert scale (1 = "very poor" to 5 = "very good"). Raw scores range from 6 to 30 and are converted into standardized T-scores (mean = 50, SD = 10). Higher T-scores indicate greater sleep disturbance (i.e., poorer sleep quality), whereas lower T-scores indicate better sleep quality.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  6. Health-Related Quality of Life

    Quality of life will be assessed using the Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL), which assesses health-related quality of life across nine domains in people with multiple sclerosis. It consists of 31 items and item is rated on a 5-point Likert scale (0 = "never" to 5 = "always"). Raw scores for each dimension and the overall score are transformed to a standardized scale ranging from 0 to 100, with higher scores indicating better health-related quality of life.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  7. Mindfulness

    Mindfulness will be assessed using the Mindful Attention Awareness Scale (MAAS) The MAAS is a self-report questionnaire that assesses the frequency with which individuals experience lapses in attention and awareness of the present moment. It consists of 15 items rated on a 6-point Likert scale (1 = "almost always" to 6 = "almost never"). The overall score is calculated as the mean of the 15 items, ranging from 1 to 6. Higher scores indicate greater dispositional mindfulness.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  8. Sleep quality

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a self-administered questionnaire that assesses sleep quality and sleep patterns over the previous month. It consists of 19 self-rated items grouped into seven components. Each component is scored from 0 to 3 (0 = no difficulty, 3 = severe difficulty), yielding a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

  9. Dispositional mindfulness

    Dispositional mindfulness will be assessed using the Five Facet Mindfulness Questionnaire (FFMQ). The FFMQ is a self-report instrument and it consists of 39 items distributed across five dimensions: observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience. Items are rated on a 5-point Likert scale ranging from 1 ("never or very rarely true") to 5 ("very often or always true"). Total scores range from 39 to 195, with higher scores indicating greater mindfulness.

    Time frame: Assessments will be performed at baseline, immediately post-intervention, 1 month post-intervention, and 3 months post-intervention.

07

Study locations

1 site
  • Hopsital Universitario Virgen Macarena
    Seville, Sevilla 41009, Spain
08

References and documents

Publications

  • Cebolla A, García-Palacios A, Soler J, Guillen V, Baños R, Botella C. Propiedades psicométricas de la validación es-pañola del Cuestionario de las Cinco Facetas de Mindful-ness (FFMQ). European Journal of Psychiatry. 2012;26(2):118-126.
  • Cebolla A, Luciano JV, DeMarzo MP, Navarro-Gil M, Campayo JG. Psychometric properties of the Spanish version of the Mindful Attention Awareness Scale (MAAS) in patients with fibromyalgia. Health Qual Life Outcomes. 2013 Jan 14;11:6. doi: 10.1186/1477-7525-11-6. PubMed 23317306 ↗
  • 23. Macías Fernández JA, Royuela Rico A. La versión española del Índice de Calidad de Sueño de Pittsburgh. Informaciones Psiquiátricas. 1996;(146):465-472.
  • Full KM, Malhotra A, Crist K, Moran K, Kerr J. Assessing psychometric properties of the PROMIS Sleep Disturbance Scale in older adults in independent-living and continuing care retirement communities. Sleep Health. 2019 Feb;5(1):18-22. doi: 10.1016/j.sleh.2018.09.003. Epub 2018 Oct 28. PubMed 30670160 ↗
  • Garcia-Campayo J, Zamorano E, Ruiz MA, Pardo A, Perez-Paramo M, Lopez-Gomez V, Freire O, Rejas J. Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health Qual Life Outcomes. 2010 Jan 20;8:8. doi: 10.1186/1477-7525-8-8. PubMed 20089179 ↗
  • Beswick E, Quigley S, Macdonald P, Patrick S, Colville S, Chandran S, Connick P. The Patient Health Questionnaire (PHQ-9) as a tool to screen for depression in people with multiple sclerosis: a cross-sectional validation study. BMC Psychol. 2022 Nov 28;10(1):281. doi: 10.1186/s40359-022-00949-8. PubMed 36443880 ↗
  • Munguia-Izquierdo D, Segura-Jimenez V, Camiletti-Moiron D, Pulido-Martos M, Alvarez-Gallardo IC, Romero A, Aparicio VA, Carbonell-Baeza A, Delgado-Fernandez M. Multidimensional Fatigue Inventory: Spanish adaptation and psychometric properties for fibromyalgia patients. The Al-Andalus study. Clin Exp Rheumatol. 2012 Nov-Dec;30(6 Suppl 74):94-102. Epub 2012 Dec 14. PubMed 23261007 ↗
  • Garcia Campayo J, Rodero B, Alda M, Sobradiel N, Montero J, Moreno S. [Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia]. Med Clin (Barc). 2008 Oct 18;131(13):487-92. doi: 10.1157/13127277. Spanish. PubMed 19007576 ↗
  • Ata E, Ozsoy-Unubol T, Demir S. Evaluation of Neuropathic Extremity Pain in Patients with Multiple Sclerosis. Noro Psikiyatr Ars. 2019 Oct 4;58(3):213-216. doi: 10.29399/npa.24802. eCollection 2021. PubMed 34526844 ↗
  • Lazaro C, Caseras X, Whizar-Lugo VM, Wenk R, Baldioceda F, Bernal R, Ovalle A, Torrubia R, Banos JE. Psychometric properties of a Spanish version of the McGill Pain Questionnaire in several Spanish-speaking countries. Clin J Pain. 2001 Dec;17(4):365-74. doi: 10.1097/00002508-200112000-00012. PubMed 11783818 ↗
  • Ehde DM, Nitsch KP, Smiley JP. Measurement characteristics and clinical utility of the Brief Pain Inventory-Short Form for individuals with multiple sclerosis. Rehabil Psychol. 2015 Nov;60(4):365-6. doi: 10.1037/rep0000065. PubMed 26618216 ↗
  • Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. A classification of chronic pain for ICD-11. Pain. 2015 Jun;156(6):1003-1007. doi: 10.1097/j.pain.0000000000000160. No abstract available. PubMed 25844555 ↗
  • Kos D, Raeymaekers J, Van Remoortel A, D'hooghe MB, Nagels G, D'Haeseleer M, Peeters E, Dams T, Peeters T. Electronic visual analogue scales for pain, fatigue, anxiety and quality of life in people with multiple sclerosis using smartphone and tablet: a reliability and feasibility study. Clin Rehabil. 2017 Sep;31(9):1215-1225. doi: 10.1177/0269215517692641. Epub 2017 Feb 17. PubMed 28786335 ↗
  • Senders A, Hanes D, Bourdette D, Carson K, Marshall LM, Shinto L. Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial. Mult Scler. 2019 Jul;25(8):1178-1188. doi: 10.1177/1352458518786650. Epub 2018 Jul 9. PubMed 29985095 ↗
  • Hughes CM, Smyth S, Lowe-Strong AS. Reflexology for the treatment of pain in people with multiple sclerosis: a double-blind randomised sham-controlled clinical trial. Mult Scler. 2009 Nov;15(11):1329-38. doi: 10.1177/1352458509345916. Epub 2009 Oct 13. PubMed 19825891 ↗
  • Senders A, Borgatti A, Hanes D, Shinto L. Association Between Pain and Mindfulness in Multiple Sclerosis: A Cross-sectional Survey. Int J MS Care. 2018 Jan-Feb;20(1):28-34. doi: 10.7224/1537-2073.2016-076. PubMed 29507540 ↗
  • Hadoush H, Alawneh A, Kassab M, Al-Wardat M, Al-Jarrah M. Effectiveness of non-pharmacological rehabilitation interventions in pain management in patients with multiple sclerosis: Systematic review and meta-analysis. NeuroRehabilitation. 2022;50(4):347-365. doi: 10.3233/NRE-210328. PubMed 35180138 ↗
  • Shkodina AD, Bardhan M, Chopra H, Anyagwa OE, Pinchuk VA, Hryn KV, Kryvchun AM, Boiko DI, Suresh V, Verma A, Delva MY. Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis. CNS Drugs. 2024 Mar;38(3):205-224. doi: 10.1007/s40263-024-01072-5. Epub 2024 Feb 29. PubMed 38421578 ↗
  • Amtmann D, Askew RL, Kim J, Chung H, Ehde DM, Bombardier CH, Kraft GH, Jones SM, Johnson KL. Pain affects depression through anxiety, fatigue, and sleep in multiple sclerosis. Rehabil Psychol. 2015 Feb;60(1):81-90. doi: 10.1037/rep0000027. Epub 2015 Jan 19. PubMed 25602361 ↗
  • Chitnis T, Vandercappellen J, King M, Brichetto G. Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes. Neurol Ther. 2022 Sep;11(3):1043-1070. doi: 10.1007/s40120-022-00368-2. Epub 2022 Jun 9. PubMed 35680693 ↗
  • Gustavsen S, Olsson A, Sondergaard HB, Andresen SR, Sorensen PS, Sellebjerg F, Oturai A. The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey. BMC Neurol. 2021 Aug 16;21(1):317. doi: 10.1186/s12883-021-02344-z. PubMed 34399707 ↗
  • Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, MacLeod MR, Fallon MT. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013 May;154(5):632-642. doi: 10.1016/j.pain.2012.12.002. Epub 2012 Dec 14. PubMed 23318126 ↗
  • Perez-Carmona N, Fernandez-Jover E, Sempere AP. [Epidemiology of multiple sclerosis in Spain]. Rev Neurol. 2019 Jul 1;69(1):32-38. doi: 10.33588/rn.6901.2018477. Spanish. PubMed 31236909 ↗
  • Wang Y, Wang J, Feng J. Multiple sclerosis and pregnancy: Pathogenesis, influencing factors, and treatment options. Autoimmun Rev. 2023 Nov;22(11):103449. doi: 10.1016/j.autrev.2023.103449. Epub 2023 Sep 21. PubMed 37741528 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Apr 2027, 7 months later.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 7 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Aug 3, 2026
StartEst.
Sep 2, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07741864
Lead sponsor
Hospital Universitario Virgen Macarena
Responsible party
Eleonora Magni (Physiotherapist and MSc, Hospital Universitario Virgen Macarena) — Principal investigator
First posted
Aug 3, 2026
Start date
Sep 2, 2026 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Eleonora Magni, MSc
Contact
magni@us.es
622623602

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion